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Protein localizationHuman papillomavirus (HPV) is a non-enveloped DNA virus with an ∼8000 base pair genome. Infection with
certain types of HPV is associated with cervical cancer, although the molecular mechanism by which HPV
induces carcinogenesis is poorly understood. Three genes encoded by HPV16 are regarded as oncogenic— E5,
E6, and E7. The role of E5 has been controversial. Expression of HPV16 E5 causes cell–cell fusion, an event
that can lead to increased chromosomal instability, particularly in the presence of cell cycle checkpoint
inhibitors like HPV16 E6 and E7. Using biochemical and cell biological assays to better understand HPV16 E5,
we ﬁnd that HPV16 E5 localizes to the plasma membrane with an intracellular amino terminus and an
extracellular carboxyl-terminus. Further, HPV16 E5 must be expressed on both cells for cell fusion to occur.
When the extracellular epitope of HPV16 E5 is targeted with an antibody, the number of bi-nucleated cells
decreases.
© 2009 Elsevier Inc. All rights reserved.Introduction
Human papillomavirus (HPV) is a double stranded DNA virus
comprised of a relatively small genome, ∼8000 bp. This family of virus
is species speciﬁc and targets epithelial cells. Approximately 6.2
million Americans are newly diagnosedwith the virus each year (CDC,
2007). Infection with certain types of HPV is associated with the
development of cervical cancer and other anogenital cancers
(Cogliano et al., 2005; McCance, 2005). More recently, it has been
reported that signiﬁcant subsets of head and neck cancers are also
HPV-positive (Gillison et al., 2000). Understanding the role of HPV in
carcinogenesis is an important ﬁrst step in developing new methods
for the timely diagnosis and treatment of these cancers.
One of the most prevalent and oncogenic HPVs is HPV16. HPV16
has been reported to be associated with ∼60% of cervical cancers
(Clifford et al., 2003) and ∼40% of head and neck cancers (Gillison et
al., 2008). The HPV16 genome is comprised of 8 genes, three of which
(E5, E6, and E7) are regarded as oncogenes based on their ability to
transform cells when expressed individually (McMurray et al., 2001).
Despite the strong correlative evidence linking HPV16 and cancer,
the exact mechanism of transformation is not fully understood. HPV
16 E6 and E7 are well established as inhibitors of the tumor
suppressor genes p53 and Rb, respectively (Jones et al., 1997;
Werness et al., 1990). In addition, both oncogenes induce genomic
instability (a hallmark of cancer), associate with a host of cellularMSB 553, College of Medicine,
klahoma City, OK 73190, USA.
).
l rights reserved.proteins, and cause other morphological changes associated with
carcinogenesis (Narisawa-Saito and Kiyono, 2007). Thus, roles for
HPV16 E6 and E7 in oncogenesis are established through unregulated
cell cycle progression and genomic changes.
HPV16 E5 is regarded as having weak transforming activity that
has been demonstrated in a number of rodent cell lines. These assays
include transformation of keratinocytes (Straight et al., 1993),
anchorage independent growth of ﬁbroblasts (Leechanachai et al.,
1992; Pim et al., 1992), immortalization of keratinocytes (Stoppler et
al., 1996), and growth stimulation of epithelial cells (Leptak et al.,
1991). When E5 is co-expressed with the E7 oncogene there is
enhanced cell transformation of rodent ﬁbroblasts (Bouvard et al.,
1994; Valle and Banks, 1995).
The collaborative role of E5 with other HPV16 oncogenes is
supported by data from transgenic mice. Expression of the HPV16 E5
oncogene under the direction of a basal epithelium speciﬁc promoter
(K14) is sufﬁcient to cause epidermal hyperplasia and the formation
of spontaneous skin tumors (Williams et al., 2005). However, tumor
size increases when the entire HPV16 genome is expressed, as
compared tomice expressing only E6 and E7 (Riley et al., 2003). These
in vitro and in vivo data are consistent with the notion that E5 can
transform cells independently as well as enhance the transforming
properties of other oncogenes.
A number of molecular mechanisms have been proposed for
HPV16 E5 in carcinogenesis. These include increasing the components
of lipid rafts (i.e. caveolin and ganglioside GM1) (Bravo et al., 2005;
Suprynowicz et al., 2008), attenuating apoptosis induced by ligand
stimulation (i.e. Fas and TNF-α, and UV irradiation) (Kabsch and
Alonso, 2002; Zhang et al., 2002), reducing cellular commu-
includingnication via gap junctions (Oelze et al., 1995), inhibiting
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plasma membrane causing an increase in antigen presentation and T-
cell recognition (Zhang et al., 2003). However, the most widely
accepted model is that HPV16 E5 associates with and inhibits the
vacuolar ATPase of the early endosome. This model proposes that
HPV16 E5 prevents acidiﬁcation of the early endosome, thereby
disrupting the endocytic trafﬁcking itinerary of the epidermal growth
factor receptor (EGFR), a prototypical tyrosine kinase receptor
frequently overexpressed in cancer (Straight et al., 1995; Thomsen
et al., 2000; Tomakidi et al., 2000).
Interestingly, many of these models for HPV16 E5 function are
inconsistent with the kinetics of HPV16 E5 expression. Based on
studies using organotypic cultures, the synthesis of HPV16 E5 mRNA
has been monitored following HPV16 infection. HPV16 E5 is
expressed soon after infection and attenuates over time (Stoler et
al., 1992). The in vitro studies complement other reports that the
HPV16 genome is frequently integrated into the host cell's chromo-
some (Schwartz et al., 1985; Stoler et al., 1992). Such cells have intact
E6 and E7, but frequently E5 is not expressed.
We have recently discovered that HPV16 E5, when expressed in
human keratinocytes causes a number of changes to cell morphology
that include increased nuclear size, percentage of bi-nucleated cells,
DNA content/cell, and tetraploidy (Hu et al., 2009). These changes are
remarkable because they are characteristics of cancerous and precan-
cerous lesions (Mittal et al., 1990; Prasad et al., 1993). We observe a
three-fold increase in bi-nucleate cells when the entire HPV16 genome
is expressed; expression of HPV16with a frameshift mutation in the E5
gene, returns the percentage of bi-nucleate cells back to basal levels
(Hu et al., 2009). Together, these data indicate that HPV16 E5 is
necessary and sufﬁcient for the formation of bi-nucleate cells.
The bi-nucleated cells that form with HPV16 E5 expression arise
through cell–cell fusion (Hu et al., 2009). Although this is a newly
reported function for HPV16 E5, the ability to induce cell fusion is a
feature of many oncogenic viruses, including Hepatitis C virus,
Hepatitis B virus, Epstein–Barr virus, Karposi sarcoma virus, and
Human T-lymphotrophic virus (Duelli and Lazebnik, 2007). Current
models for how cell fusion contributes to oncogenesis suggest that
following cell fusion, most bi-nucleated cells become quiescent or
apoptotic, but those that can replicate have an increased potential to
mis-segregate chromosomes, as the cell is not equipped to divide
twice the number of chromosomes during cell division. The
probability of fused cells continuing to replicate is low, which is
consistent with estimates of in vivo cell transformation. If cell cycle
checkpoint inhibitors are expressed following cell fusion, the
potential for chromosomal instability increases, as has been recently
demonstrated using non-oncogenic viruses (Duelli et al., 2007).
Our recent data studying oncogenes of HPV16 is consistent with
this model. Cells that fuse following expression of HPV16 E5 have an
increased potential to undergo transformationwhenHPV16 E6 and E7
are expressed (Hu et al., 2009). The established roles of HPV16 E6 and
E7 in the inhibition of proteins that regulate cell cycle checkpoints
(Jones et al., 1997; Werness et al., 1990), and are postulated to help
the cells with twice the chromosomal content propagate. With
multiple rounds of cell division, the potential for errors in chromo-
somal segregation increases, and with it, the chance for cell
transformation.
The incidence of cell–cell fusion occurs with low frequency in
tissue culture cells and likely occurs with even lower frequency in
patients. According to the Center for Disease Control, there are an
estimated 20 million HPV-positive individuals in the United States,
but only ∼25,000 HPV-associated cancers/year. Clearly, progression
from an HPV-positive status to developing cancer is a rare event.
Understanding the molecular mechanism by which HPV16 E5
mediates cell fusion is the ﬁrst step in developing potential strategies
to inhibit cell–cell fusion and the initiation of carcinogenesis. In this
study, we have employed a series of cell biological and biochemicalassays to determine the features of HPV16 E5 that allow it to mediate
cell fusion. We have found that HPV16 E5 is expressed at the plasma
membrane and oriented such that the amino terminus is intracellular
and the carboxyl-terminus is extracellular. For cell fusion to occur,
both cells require expression of HPV16 E5. The addition of an antibody
to the protein's extracellular domain can inhibit cell fusion. These
ﬁndings provide an important foundation for understanding the
molecular regulation of cell fusion by HPV16 E5.
Results
The role of HPV16 E5 protein has been difﬁcult to discern. Barriers
to the study of this protein include low levels of protein expression,
poor protein expression, and a paucity of reagents for detecting the
protein. In order to overcome these obstacles, we generated
tetracycline-regulatable (‘tet-off’) adenoviruses that express a hema-
gluttinin (HA) tagged, codon optimized form of the protein. The
adenoviruses, termedHPV16 HA-E5 and HPV16 E5-HA, encode the HA
epitope on either the amino- or carboxyl-terminus, respectively.
These adenoviruses can only be expressed in cells that express the
tetracycline transactivator (tTA), a chimeric protein that constitu-
tively binds and activates the tetracycline promoters, except in the
presence of tetracycline (Gossen and Bujard, 1992). We stably
transfected the tTA in the spontaneously immortalized, human
keratinocyte cell line, HaCaT cells. HaCaT cells are a HPV-negative
cell line that is frequently used to study the function of HPV genes.
These cells are referred to as tTA-HaCaT cells and used throughout this
study. This expression system undoubtedly expresses HPV16 E5 at
levels that exceed those that occur following infection with the native
virus. However, the progression of HPV infection into a cancer is a rare
event, and overexpression of oncogenes facilitates the detection of
rare, but important, cellular events.
As reported previously, we have found that expression of HPV16
E5 causes cell fusion (Hu et al., 2009). This is demonstrated using a
YFP-reporter assay in which tTA-HaCaT cells are transfected with
either T7 RNA polymerase (pRK-T7 RNA polymerase) or YFP driven by
a T7 promoter (pT7-YFP), mixed in a 1:1 ratio, infected with HPV16
E5, and examined for the presence of YFP-positive cells as measured
by FACS (schematic shown in Fig. 1A) (Hu et al., 2008). This high-
throughput assay allows the rapid measure of fused cells, as only
when the cytosol of the two differentially transfected cells mix is the
ﬂuorescent protein produced (Fig. 1B). As shown in Fig. 1C, expression
of the HPV16 HA-E5 or HPV16 E5-HA causes a 5-8 fold increase in the
YFP ﬂuorescence intensity. Cells infected with the HPV16 E5
adenoviruses in the presence of tetracycline do not express the
protein (Fig. 1D) or cause the cells to fuse (Fig. 1C). Thus, cells fusion is
mediated by HPV16 E5 expression and is not an indirect consequence
of adenovirus infection.
HPV16 E5 is expressed on the plasma membrane
In order to gain insight into the molecular mechanism by which
HPV16 E5mediates cell fusion, wewanted to knowwhere in the cell it
was expressed. A common characteristic of fusogenic proteins is that
they are transmembrane proteins expressed on the cell surface. To
determine if this was the case for HPV16 E5, we isolated the plasma
membranes of cells expressing either HPV16 HA-E5 or HPV16 E5-HA
using the Qiagen Qproteome plasma membrane puriﬁcation system
as described in Materials and methods.
For this experiment, we used the epidermal growth factor receptor
(EGFR) as a positive control for plasma membrane puriﬁcation.
Glyceraldehyde-3-phosphate dehydrogenase (GADPH) is a cytosolic
protein and used to monitor non-speciﬁc protein isolation (Fig. 2).
Both HPV16 HA-E5 and HPV16 E5-HA were present in the membrane
fraction (Fig. 2). Since this is a non-quantitative assay, we cannot
accurately estimate the percentage of HPV16 E5 that localizes to the
Fig. 1. Expression of HPV16 E5 causes cell to fuse. A. Schematic of cell fusion assay used in this study. Separate populations of tTA-HaCaT cells were transfected with either pRK-T7
RNA polymerase or pT7-YFP, mixed in a 1:1 ratio, and infected with either adenovirus encoding HPV16 HA-E5 or HPV16 E5-HA in the present or absence of tetracycline. Cells were
incubated for 72 h. B. Following incubation, cells were ﬁxed and stained with DAPI. Shown are representative images of YFP-positive, bi-nucleated cells generated in the cell fusion
assay. Size bar=10 μm. C. Cells were collected and sorted by FACS to assess the number of YFP-positive cells. Data are the normalized (to uninfected cells) total ﬂuorescence intensity
(percentage of positive cells times the mean ﬂuorescence intensity). Shown are the average±S.E.M. (n=3). D. The remaining cell lysates were collected after ﬂow cytometry and
were resolved on a 16% Tris-tricine gel and immunoblotted with the 12CA5 (anti-HA) antibody or α-tubulin as a loading control. ⁎ indicates pb0.01 (student's t-test).
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the HPV16 E5 is localized to the plasma membrane based on the
relative levels of protein detected and the amounts loaded. HPV16 E5
has been reported to localize to a variety of cellular compartments,
including early endosome, Golgi, and nuclear membrane (Conrad et
al., 1994; Disbrow et al., 2005; Oelze et al., 1995, 2000; Straight et al.,
1995). Based on the indirect immunoﬂuorescence data (Fig. 3), it is
likely that the remainder of the HPV16 E5 protein has localized to one
of these other locations.
Regardless of the exact percentage of HPV16 E5 that localizes to
the plasmamembrane, the level is sufﬁcient to induce cell–cell fusion,
both when HPV16 E5 is expressed alone or in the context of the entire
genome (Hu et al., 2008). In addition, this experiment demonstrates
that the location of the HA epitope does not affect targeting to the
plasma membrane localization.Fig. 2. Biochemical evidence HPV16 E5 is enriched in the plasma membrane. tTA-HaCaT
cells were infected with nothing (uninfected), HPV 16 HA-E5, or HPV16 E5-HA
adenoviruses. Forty-eight hours post-infection, the cells were harvested, and the
plasma membrane was isolated from the infected cells (Qproteome plasma membrane
protein puriﬁcation, Qiagen). For the GAPDH and E5 detection, the total (Total) and
plasma membrane (PM) fractions (5% and 50%, respectively) were resolved using 16%
Tris-tricine polyacrylamide gel and immunoblotted with antibodies against GAPDH and
12CA5. The EGFR was detected by resolving total and plasma membrane fractions (5%
and 50%, respectively) on a 7.5% SDS-PAGE gel and immunoblotting with an EGFR
antibody (sc-03, Santa Cruz Biotechnology). Shown is a representative experiment
repeated three times.Having localized HPV16 E5 to the plasma membrane, we next
wanted to determine its orientation in the membrane. To answer
this question, we infected tTA-HaCaT cells with either HPV16 HA-
E5 or HPV16 E5-HA. After infection, cells were subjected to
indirect immunoﬂuorescence with or without membrane permea-
bilization (Fig. 3A). In cells that are permeabilized, both the
HPV16 HA-E5 and the HPV16 E5-HA can be detected. However, in
the absence of permeabilization, only the HPV16 E5-HA can be
detected.
Since the morphology of HaCaT cells is relatively ﬂat, it is difﬁcult
to discern whether the protein is localized on the plasma membrane
using wide-ﬁeld microscopy. To combat this problem, we examined
the distribution of HPV16 E5-HA on HaCaT cells relative to a plasma
membrane localized protein, the epidermal growth factor receptor
(EGFR). HaCaT cells that had been transduced with HPV16 E5-HA
adenovirus were subjected to indirect immoﬂuorescence using
antibodies against the HA-tagged E5 (red) and EGFR (green) in the
absence or presence of membrane permeabilization (Fig. 3B). In
unpermeabilized cells, the distribution of HPV16 E5-HA is similar to
that of the EGFR. However, when the cells were permeabilized, there
is some staining for HPV16 E5-HA (as well as the EGFR) in the
cytoplasm, indicating only a portion of the E5 is localized to the
plasma membrane.
These data are corroborated by analysis of the 12CA5 (anti-HA)
antibody binding to intact cells and sorting by Fluorescent Assisted
Cell Sorting (FACS). There is an increase in cell-associated ﬂuores-
cence in cells infected with HPV16 E5-HA, but not those expressing
HPV16 HA-E5 (Fig. 4A). For both proteins, ﬂuorescence returns to
background levels (uninfected cells) when tetracycline is added to
ablate protein expression.
From these two different assays, we demonstrate that HPV16 E5 is
expressed on the cell surface with the amino terminus intracellular
and the carboxyl-terminus extracellular. Based on the plasma
membrane puriﬁcation data, we know both proteins are expressed
on the plasma membrane and we can be conﬁdent that differences in
protein detection reﬂect the protein's orientation.
Fig. 3. Indirect immunoﬂuorescence data localizing HPV16 E5 to the plasmamembrane.
A. tTA-HaCaT cells were infected with HPV16 HA-E5, or HPV16 E5-HA. Forty-eight
hours post-infection, cells were ﬁxed and permeabilized with or without 1 mg/ml
saponin. Cells were processed for indirect immunoﬂuorescence and stained with DAPI
as described in Materials and methods. Shown are representative images from an
experiment repeated three times. Size bar=10 μm. B. tTA-HaCaT cells were infected
with adenovirus encoding HPV16 E5-HA, and processed for indirect immunoﬂuores-
cence using antibodies against the HA tag (Y-11, Santa Cruz Biotechnology) (green) and
the EGFR (Ab-1, Calbiochem) (red). Cells were ﬁxed and stained with DAPI (blue).
Shown are the individual confocal sections of the red and green channels, as well as the
merged images including the DAPI stain. For the merged image the horizontal and
vertical z-stacks are shown below and to the right of the merged images. Size
bar=10 μm.
Fig. 4. HPV16 E5 is oriented with an intracellular amino terminus and an extracellular
carboxyl terminus. A. tTA-HaCaT cells were infected with nothing or either adenovirus
encoding HPV16 HA-E5, or HPV16 E5-HA in the absence or presence of 1 μg/ml
tetracycline, as indicated. Forty-eight hours post-infection, cells were collected, and a
suspension of intact cells was incubated with the 12CA5 antibody for 1 h at 4 °C, washed
extensively and incubated with an Alexa488-conjugated goat anti-mouse secondary
antibody for 1 h at 4 °C, followed by more washing. Cells were sorted by FACS to
determine the mean ﬂuorescent intensity associated with the cells. Data are plotted as
the fold change in ﬂuorescent mean intensity as compared to uninfected cells. Data are
plotted as the average±S.E.M. (n=4). ⁎ indicates pb0.01 (student's t-test).
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Knowing that the HPV16 E5 is expressed on the plasma
membrane, we wanted to know whether cell fusion required
expression of the protein on both cells. If only one cell required
protein expression that would suggest HPV16 E5 was binding a
receptor on its neighboring cell. Conversely, if both cells require
expression of HPV16 E5 that would be evidence that either the two
proteins directly interact with one another or indirectly interact via a
protein or protein complex. This distinction is important for the
design of antagonists to cell fusion.
To assess whether HPV16 E5 is needed on both cells for fusion,
we ﬁrst used a single cell assay to monitor the formation of
heterokaryons (see Fig. 5A for schematic of experimental design).
Nuclei of different cell populations were labeled with either red
ﬂuorescent protein — histone 2B (RFP-H2B) or yellow ﬂuorescent
protein-histone 2B (YFP-H2B) and mixed in a 1:1 ratio. Cells were
then infected with adenovirus encoding HPV16 HA-E5. Cells were
then monitored for the formation of heterokaryons — bi-nucleated
cells expressing both a red and green labeled nuclei (Figs. 5B–G).
tTA-HaCaT cells were used to express HPV16 E5. When it was desired
that a cell population not express HPV16 E5, parental HaCaT cells
were used. The parental HaCaT cells do not express HPV16 E5
following infection (Fig. 5H). Shown in Figs. 5B–D are representative
micrographs of cells with nuclei labeled with RFP-histone2B and
YFP-histone 2B with HPV16 E5 expression. Under these conditions,
we observed heterokaryons (Fig. 5B), as well as cells with enlarged
nuclei with both ﬂuorescent labels (Figs. 5C–D). Enlarged nuclei are
another characteristic of HPV16 E5-expressing cells1. Quantiﬁcation
of heterokaryons reveals that approximately 10% of bi-nucleated
cells are heterokaryons when both cells express HPV16 E5 (Fig. 5H),
which is consistent with our previous ﬁndings (Hu et al., 2009). In
contrast, when only one population of ﬂuorescently-labeled cells
expresses HPV16 E5, we observed cells with enlarged nuclei in the
HPV16 E5 expressing cells, but no heterokaryons (Figs. 5E and F).
Cell populations with no HPV16 E5 have no heterokaryons or
changes in nuclear size (Fig. 5G).
These data are consistent with our ﬁndings using the YFP-reporter
assay (Fig. 6A). This assay allows us to look at large populations of
cells and to quantify changes in cell fusion. Much like what was seen
in the microscopy based assays, we detect increased cell fusion only1 L. Hu and B. Ceresa, personal communication.
Fig. 5. Heterokaryons only form when both cells express HPV16 E5. A. Schematic of experimental design. Brieﬂy, tTA-HaCaT and parental HaCaT cells were transfected with either
histone 2B-red ﬂuorescent protein (H2B-RFP) or histone 2B-yellow ﬂuorescent protein (H2B-YFP) to mark the nuclei. Combinations of tTA-HaCaT or HaCaT cells expressing H2B-RFP
were mixed with cells expressing H2B-YFP. Cells were infected with HPV16 HA-E5 adenoviruses. Only cells stably transfected with the tTA expressed the adenoviral protein. After
72 h post-infection, cells were subjected to indirect immunoﬂuorescence using the anti-HA antibody and a Alexa 647-conjugated goat anti-mouse secondary antibody (blue). Shown
are representative images from three separate experiments. B–D) Both populations of cells express HPV16 HA-E5, E) Only cells with red nuclei express HPV16 HA-E5. F) Only cells
with green nuclei express HPV16 HA-E5. G) Neither cell population expresses HPV16 HA-E5. Size bar=10 μm. H) Shown is the average percentage of bi-nuclei cells (±S.E.M.) in
different cell population from three experiments (n=690–1530 cells/condition).
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HPV16 E5, the change in cell fusion is not statistically different from
control (HPV16 E5 negative) cells.Together, these data indicate that either HPV16 E5 is forming a
dimer with itself or the two proteins are interacting via a bridge
protein or protein complex. Importantly, these data eliminate the
Fig. 6. Cell fusion requires expression of the HPV16 E5 on both cells. As a secondary
approach to quantify cell–cell fusion, a derivation of the approach shown in Fig. 5A was
used. tTA-HaCaT cells and parent HaCaT cells were transfected with either pRK T7-RNA
polymerase or pT7-YFP. Either tTA-HaCaT or HaCaT cells expressing pRK T7-RNA
polymerase were mixed with either tTA-HaCaT or HaCaT cells expressing pT7-YFP, such
that all four possible combinations of cells were mixed. Cells were infected with HPV16
HA-E5 adenoviruses and only tTA-HaCaT cells expressed the HPV16 HA-E5, thus
allowing HPV16 HA-E5 to be differentially co-expressed with pRK T7-RNA polymerase
or pT7-YFP. Cells engineered to express HPV16 HA-E5 are indicated by “+E5”, whereas
those that do not are marked as “−E5”. After 72 h, cells were collected and sorted by
FACS to assess the number of YFP-positive cells (indicating mixing of cytosols). A) Data
are plotted as the fold increase in total ﬂuorescence intensity (percentage of positive
cells times the mean ﬂuorescence intensity). Shown are the average±S.E.M. (n=3). ⁎
indicates pb0.01 (student's t-test) as compared to cells expressing HPV16 E5 in only
one cell. B) Cells collected from (A) were lysed, resolved by 16% Tris-tricine gel, and
immunoblotted for the presence of HPV16 HA-E5 using an anti-HA antibody (12CA5) or
α-tubulin (Sigma) as a loading control.
Fig. 7. Antibody inhibition of HPV16 E5-HA cell fusion. tTA-HaCaT cells were infected
with either A) HPV16 E5-HA or B) HPV16 HA-E5. Immediately following infection, cells
were incubated with no antibody, 12CA5 (anti-HA 1:250) or 9E10 (anti-myc, 1:250).
Cells were incubated additional 72 h, ﬁxed, and stained with Dapi. Cells were scored for
the number of bi-nucleated cells. Data are plotted as the percentage of bi-nucleated
cells found in each population (the average±S.E.M.; n=3). ⁎ indicates pb0.01
(student's t-test) as compared to cells without the 12CA5 antibody.
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has been shown by others (Gieswein et al., 2003), and repeated by us
(data not shown) that HPV16 E5 forms oligomeric complexes with
itself. We have not been able to demonstrate that HPV16 E5 on
neighboring cells can form a complex. That will be the focus of future
studies.
We observe a disproportionate decrease in protein expression
when only one population of cells expresses HPV16 E5 (Fig. 6B). Based
on our indirect immunoﬂuorescence analysis of HA-positive cells, this
is not a function of the initial level of HPV16 HA-E5 expression. One
explanation for the differences is the growth advantage that is
conferred to unfused, HPV16 E5-negative cells. We have observed
previously that bi-nucleate cells that form following HPV16 HA-E5
expression fail to proliferate (Hu et al., 2009). Thus, despite the two
different populations of cells being plated and infected at a 1:1 ratio,
72 h after introduction of HPV16 E5, the HPV16 E5-negative cells will
have grown more. When HPV16 HA-E5 expression is assayed based
on loading equivalent amounts of protein, b50% of the cells are HPV16
E5 positive. When both populations express HPV16 E5, neither
population has a growth advantage over the other and the level of
HPV16 HA-E5 expression is higher relative to total protein.
However, these differences in growth among the two cell
populations do not effect the interpretation of the data, as ratio ofthe two cell populations (based on cell counting and infection
efﬁciency) is 1:1 initially. Only after cell fusion begins to occur do
the ratios change.
Cell fusion can be inhibited by antibody binding to the extracellular
domain of HPV16 E5
To determine if HPV16 E5-mediated cell fusion could be inhibited,
we expressed either HPV16 HA-E5 or HPV16 E5-HA in HaCaT cells.
Following infection, cells were incubated with the 12CA5 (anti-HA)
antibody for 72 h, ﬁxed, DAPI stained, and examined under the
microscope for the presence of bi-nucleated cells (Fig. 7). As observed
in the past, there was a 4-fold increase in the percentage of bi-
nucleated cells with HPV16 E5-HA expression (Hu et al., 2009). The
addition of the 12CA5 antibody attenuated the formation of bi-
nucleated cells to levels observed when E5 expression was abrogated
by the addition of tetracycline. The addition of the 9E10 (anti-myc
epitope) had no effect on the percentage of bi-nucleated cells.
Importantly, in cells expressing HPV16 HA-E5, the addition of the
12CA5 antibody did not alter the levels of bi-nucleated cells. Thus,
antibody binding to the extracellular portion of HPV16 E5 prevents
fusion, presumably through sterically hindering an interaction of the
protein with the requisite molecules for cell fusion. It is not known if
the interacting protein is another HPV16 E5 molecule or a bridging
intermediate. Regardless of the exact mechanism, this ﬁnding
provides proof of principle that HPV16 E5-mediated cell fusion can
be inhibited by the addition of extracellular molecules.
Discussion
In this manuscript, we demonstrate that the fusogenic HPV16 E5 is
expressed on the plasma membrane of cells and is oriented with its
amino terminus inside the cell and the carboxyl-terminus outside the
cell. Our data show that both cells must express HPV16 E5 for cell–cell
fusion to occur, indicating that E5 cannot induce cell–cell fusion
through an interaction with another protein (receptor) on a
neighboring cell, but rather forms an E5–E5 dimer or a complex
containing at least two HPV16 E5 molecules. These ﬁndings provide
important insight into how the fusogenic process is mediated.
Cell–cell fusion is a common occurrence in biology. It is observed
in diverse processes from fertilization, muscle and bone development,
immune response, and tissue regeneration (Chen and Olson, 2005).
Despite the well-established roles for cell–cell fusion in these
processes, very little is understood regarding how this process is
mediated.
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include localization to the plasma membrane, high level of
hydrophobicity, and the ability for form dimers (Gieswein et al.,
2003; Martin and Ryuysschaert, 2000). However, mechanistically,
little is known how fusion is mediated. Our data regarding the
localization and orientation of the HPV16 E5 protein will be useful
for elucidating the molecular details regarding how cell–cell fusion
occurs.
Despite the knowledge that many oncogenic viruses are able to
promote cell–cell fusion, a deﬁnitive link between cell–cell fusion
and carcinogenesis has only been established recently (Duelli and
Lazebnik, 2007; Duelli et al., 2007). Based on recent ﬁndings and
the subsequent models, it is easy to see why delineating a role for
cell–cell fusion in oncogenesis has been difﬁcult. Under most
conditions, fused cells become quiescent or undergo apoptosis (Hu
et al., 2009) and are irrelevant to cancer progression as they are not
involved in tumor formation. Those cells that escape quiescence/
apoptosis and do divide, appear to be mononucleated. Thus, the bi-
nucleated cells are transient. These mononucleated cells are
characterized by an increased incidence of chromosomal abnormal-
ities — gain or loss of chromosomes or structural abnormalities
(Duelli et al., 2007). Such chromosomal changes, or aneuploidy, are
hallmarks of cancer cell. Thus, since cell–cell fusion is rare event
coupled with the fact that the presence of bi-nucleated cells are
transient, observing, tracking, and understanding these events has
been difﬁcult. Knowing the basic cell biology of the HPV16 E5
protein will facilitate the design of reagents that will inhibit cell–
cell fusion, enhance cell fusion, and understand the fate of cell that
have fused.
In order to better understand the role of cell–cell fusion in
developmental and cancer biology, it is critical that cell biological
and biochemical properties of these proteins be better understood.
Having identiﬁed the cellular location, orientation, and a strategy
for inhibiting HPV16 E5-mediated cell–cell fusion, we provide
“proof of principle” evidence that E5 can serve as a target to inhibit
cell–cell fusion. These data will be the basis for future studies that
target the native HPV16 E5 protein to study and prevent cell
transformation.
Materials and methods
Generation of tTA-HaCaT cells
HaCaT cells were retrovirally infected with the tetracycline
transactivator (tTA) (Clontech Retroviral GeneTransfer and Expres-
sion System). Neomycin resistant colonies were grown in 800 μg/ml
G418. Individual colonies were isolated, ampliﬁed, and screened
based on their ability to regulate expression of tetracycline-regula-
table adenovirus.
Parental HaCaT and tTA-HaCaT cells were maintained in Dulbec-
co's Minimal Essential Media (DMEM) supplemented with 10% fetal
bovine serum (FBS), 100 U/ml penicillin, 100 U/ml streptomycin, and
2 mM glutamine. Cells stably transfected with tTA were maintained in
800 μg/ml G418. All three cell linesweremaintained at 37 °C in 5% CO2
(Hu et al., 2009).
Adenovirus generation/expression
Codon optimized HPV16 E5 was generated as previously described
(Disbrow et al., 2003). A hemagglutinin (HA) epitope (MEYDVP-
DYAH) was engineered on to either the amino (HA-E5) or carboxyl
(E5-HA) terminus of the protein by PCR, making the appropriate
modiﬁcation of stop codons. Adenoviruses were generated using
Clontech Adeno-X™ Tet-off expression system. All adenoviruses were
sequenced at the DNA sequencing facility at the Oklahoma Medical
Research Foundation (Hu et al., 2009).Plasmids and transfection
HA-tagged, codon optimized HPV16 E5 was generated as de-
scribed above and subcloned into the pcDNA3 (Invitrogen). DNA
(4 μg) was transfected into cells via nucleotransfection using the
Amaxa transfector (Amaxa) according to manufacturer's directions
(Hu et al., 2009).
Adenoviral infection
Cells were plated at 75% conﬂuency and infected at a multiplicity
of infection of 20 plaque forming units/cell. Adenoviruses were
cesium chloride puriﬁed and diluted in DMEM for infection. After 2 h
of incubation with adenovirus, virus containing media was removed
from the cells and replacedwith growthmedia and allowed to recover
for 24–48 h.
Indirect immunoﬂuorescence
Indirect immunoﬂuorescence was performed as previously de-
scribed (Dinneen and Ceresa, 2004). Cells were ﬁxed in 4% para-
formaldehyde and either permeabilized with 0.01% saponin or left
intact. The mouse monoclonal 12CA5 (anti-HA, Roche) (diluted
1:1000) and anti-EGFR (Ab-1, Calbiochem) (diluted 1:1000) and
rabbit polyclonal antibody anti-HA (Y-11, Santa Cruz Biotechnology)
(diluted 1:500), were the primary antibodies and Alexa 488-, Alexa
568-, or Alexa 647-conjugated goat anti-mouse or anti-rabbit
(Molecular Probes) as the secondary antibody at a dilution of 1:250.
Cells were also stained with 10 ng/ml DAPI (Sigma). Images were
captured using Olympus AX70 epiﬂuorescent microscope with Q-
Capture software or Olympus Confocal FV100 microscope and
analyzed using the Olympus Fluoveiw Software.
Assessment of bi-nucleation
Images of DAPI stained nuclei were analyzed using Photoshop
software. Bi-nucleated cells were calculated as the number of cells
with two nuclei divided by the total cells.
Heterokaryon formation assay
tTA-HaCaT cells or parental HaCaT cells (2×106 cells) were
transfected with pRK7-histone 2B-RFP (1.5 μg plasmid) or pRK7-
histone 2B-YFP (1.5 μg plasmid) by nucleofection using the Amaxa
Nucleofector I (transfection efﬁciency ∼70%). After 24 h recovery,
cells were mixed in a 1:1 ratio and then infected with HA-E5
adenovirus (20 pfu/cell). After 72 h, cells were ﬁxed and observed by
ﬂuorescence microscopy for bi-nucleated cells.
YFP cell fusion reporter assay
tTA-HaCaT cells or parental HaCaT cells were transfected by Amaxa
nucleofection with either a plasmid expressing T7 RNA polymerase
(pRK-T7 RNA polymerase) or yellow ﬂuorescent protein (YFP) driven
by a T7 promoter (pT7-YFP). Following 16 h of recovery, cells were
washed, and re-plated with 200,000 cells of each population (1:1
ratio) into a well of a 12-well dish. Cells were infected with
adenovirus as indicated in the ﬁgure legend using the method
described above. Seventy-two hours post-infection, cells were
collected, washed in PBS, and analyzed using a FACS Calibur (Becton
Dickinson). The data from 10,000 cells/experiment were analyzed
using Cell Quant Pro (Becton Dickinson, Version 5.2.1 software). Data
were plotted as the relative increase in the total YFP intensity
(percentage of positive cells multiplied by their ﬂuorescent mean
intensity) as compared to cells without virus infection (Hu et al.,
2008).
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tTA-HaCaT cells were infected with either HPV16 HA-E5 or HPV16
E5-HA 3.5×104 cells/well of a 24-well tissue culture dish. Immedi-
ately following infection, cells were incubated with no antibody,
12CA5 (anti-HA 1:250) or 9E10 (anti-myc, 1:250). Cells were
incubated additional 72 h, ﬁxed, and stained with Dapi. Cells were
scored for the number of bi-nucleated cells.
Plasma membrane puriﬁcation
The plasma membranes of HPV16 HA-E5 or E5-HA infected tTA-
HaCaT cells were isolated using the non-quantitative Qproteome
puriﬁcation kit (Qiagen) according to the manufacturer's directions.
Brieﬂy, cells are lysed by incubation in a hypotonic buffer containing a
mild buffer, and membranes are mechanically disrupted using a 21
gauge needle and syringe. Membranes are incubated with a
proprietary ligand speciﬁc for molecules on the plasma membrane.
The ligand and associated plasma membranes are isolated using
magnetic beads that have been engineered to capture the ligand.
Fractions of the total (5%) and plasmamembrane (50%) were resolved
by SDS-PAGE and immunoblotted with antibodies against the EGFR
(sc-03, Santa Cruz Biotechnology), glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) (sc-47724, Santa Cruz). The unstimulated
EGFR localizes primarily to the plasma membrane and served as a
positive control for puriﬁcation; GADPH is a cytosolic protein and
served as a negative control.
Analysis of cell surface expression of HPV16 E5
tTA-HaCaT cells were infected with nothing or adenoviruses
encoding HPV16 HA-E5 or E5-HA in the absence and presence of
1 μg/ml tetracycline to regulate protein expression. After 48 h post-
infection, adherent cells were incubated in 5 mM EDTA/PBS pH 7.4
and collected. Cells were washed two times in PBS and re-suspended
with the anti-HA mouse monoclonal antibody (12CA5, Roche) for 1 h
on ice. Unbound antibody was removed by diluting the cell
suspension in PBS and gently pelleting the cells (three times). After
the ﬁnal wash, cells were re-suspended in PBS with a Alexa488
conjugated goat anti-mouse secondary antibody (Molecular Probes),
and incubated for 1 h on ice. After three more washes in PBS as
described above, cells were re-suspended at a concentration of
∼1×106 cells/ml. Fluorescently tagged cells were assessed by FACS.
Data are plotted as the relative level of cell-associated ﬂuorescence as
compared to uninfected cells.
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